Clinical Trial Update: Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib plus etoposide as first-line therapy in osimertinib-resistant advanced EGFR-mutant non-small cell lung cancer; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Etoposide (Etoposide)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: NOT_YET_RECRUITING